Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors
September 29, 2010
In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:
Medicare product coverage strategy
Proper planning for product pricing
Preparing comparative effectiveness data
Working with payer expectations
Data that should be in place for partnering or acquisition deals
Panelists:
Judith A. Waltz, Partner, Foley & Lardner LLP
Anita Chawla, Ph.D., Vice President, Analysis Group
Related Insights
March 31, 2026
Foley Viewpoints
Coming Soon to Procurement Contracts – A Contract Clause Prohibiting Certain DEI Activities
On March 26, 2026, the President issued Executive Order 14398 titled “Addressing DEI Discrimination by Federal Contractors.” The Order…
March 31, 2026
Energy Current
Public Utility Commission of Texas Issues Proposed Rules for Large Load Interconnections; What Data Center and AI facility Developers Need to Know
1. Statutory Mandates: The Foundation of SB 6 Senate Bill 6, which was enacted in June 2025 (89th Legislature), requires the PUCT to…
March 31, 2026
Innovative Technology Insights
White House Unveils Framework for Artificial Intelligence Regulation
The Trump Administration has introduced the National Policy Framework for Artificial Intelligence, which calls on Congress to create a uniform federal standard that would preempt the current patchwork of state laws.